Rachel Haurwitz is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and in 2014, was named by Forbes magazine to the "30 Under 30" list in Science and Healthcare. She is also a co-founder of Intellia Therapeutics where she is a member of the board of directors. Dr. Haurwitz is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high-impact journals characterizing CRISPR-Cas systems. She earned an AB in Biological Sciences from Harvard College and a PhD in Molecular and Cell Biology from the University of California, Berkeley.